|
J Biol Chem, Vol. 275, Issue 2, 717-720, January 14, 2000
ACCELERATED PUBLICATION
Pharmaco-topology of Sulfonylurea Receptors
SEPARATE DOMAINS OF THE REGULATORY SUBUNITS OF
KATP CHANNEL ISOFORMS ARE REQUIRED FOR SELECTIVE
INTERACTION WITH K+ CHANNEL OPENERS*
Andrey P.
Babenko ,
Gabriela
Gonzalez, and
Joseph
Bryan
From the Department of Molecular and Cellular Biology, Baylor
College of Medicine, Houston, Texas 77030
 |
ABSTRACT |
The differential responsiveness of
(SUR1/KIR6.2)4 pancreatic -cell
versus (SUR2A/KIR6.2)4 sarcolemmal
or (SUR2B/KIR6.0)4 smooth muscle cell
KATP channels to K+ channel openers
(KCOs) is the basis for the selective prevention of hyperinsulinemia,
myocardial infarction, and acute hypertension. KCO-stimulation of
KATP channels is a unique example of functional coupling between a transport ATPase and a K+ inward
rectifier. KCO binding to SUR is Mg-ATP-dependent and antagonizes the inhibition of (KIR6.0)4 pore
opening by nucleotides. Patch-clamping of matched chimeric human
SUR1-SUR2A/KIR6.2 channels was used to identify the SUR
regions that specify the selective response of sarcolemmal
versus -cell channels to cromakalim or pinacidil
versus diazoxide. The SUR2 segment containing the 12th through 17th predicted transmembrane domains, TMD12-17, confers sensitivity to the benzopyran, cromakalim, and the pyridine, pinacidil, whereas an SUR1 segment which includes TMD6-11 and the first
nucleotide-binding fold, NBF1, controls responsiveness to the
benzothiadiazine, diazoxide. These data are incorporated into a
functional topology model for the regulatory SUR subunits of
KATP channels.
 |
INTRODUCTION |
K+ channel openers,
KCOs,1 are a structurally
diverse group of compounds with no obvious common pharmacophore linking
their ability to antagonize the inhibition of ATP-sensitive
K+ (KATP) channels by intracellular
nucleotides (1). After the identification of
KATP channels in cardiomyocytes and pancreatic -cells using the patch-clamp technique (2, 3), Trube et al. (4) showed the benzothiadiazine KCO, diazoxide, stimulates -cell KATP channels, and Escande et
al. (5) reported the benzopyran KCO, cromakalim, increased the
activity of sarcolemmal channels in inside-out membrane patches
indicating a direct interaction with these channels. Cloning of
-cell and sarcolemmal KATP channel subunits
led to the understanding that they are
(SUR1/KIR6.2)4 and
(SUR2A/KIR6.2)4 complexes, respectively, and
that their differential responses to KCOs and to sulfonylureas are
determined by the SUR isoform (Refs. 6-8, and reviewed in Ref. 9).
Recent studies have shown that pharmacologically significant binding of
the pyridine KCO, [3H]P1075, an analog of the potent
"cardiovascular" KCO, pinacidil (10), to SURs requires hydrolyzable
nucleotide triphosphates, Mg2+ or Mn2+, and
intact nucleotide-binding folds (both NBF1 and NBF2) (11-13). Diazoxide does not stimulate homomeric KIR6.2 channels (14) and [3H]P1075 does not interact with KIR6.0
(13). The effect of diazoxide on native and reconstituted sarcolemmal
channels in the presence of quasi-cytosolic [Mg-ATP] is negligible in
comparison with stimulation by both cromakalim and pinacidil (1, 9,
15). SUR2A/KIR6.2 channels can be stimulated by diazoxide
at supra-physiologic [ADP]i and submillimolar
[ATP]i in the presence of Mg2+
(16). This suggests diazoxide can bind to SUR2s in agreement with the
stimulation of SUR2B/KIR6.2 channels (17) and with the
displacement of [3H]P1075 from both SUR2 isoforms,
differing in their final 42 amino acids, by diazoxide (13). By
exchanging segments between SUR1 and SUR2A, D'Hahan et al.
(18) have shown the importance of the C-terminal set of transmembrane
domains of SUR2 for stimulation of KATP channels
by SR47063, a cromakalim analog. Uhde et al. (19) were able
to identify two smaller sequences within this region critical for
[3H]P1075 binding and stimulation.
We have used matched human SUR1-SUR2A chimeras, previously employed to
define the segments critical for SUR isoform-specific ATP-inhibitory
gating (20) and high-affinity tolbutamide inhibition (21), to validate
the requirement of TMD12-17 of SUR2 for stimulation by cromakalim or
pinacidil and to demonstrate that TMD6-11 and NBF1 control the
responsiveness to diazoxide in the presence of Mg-ATP.
 |
EXPERIMENTAL PROCEDURES |
The human SUR1, SUR2A, and KIR6.2 cDNAs have
been described previously (22), as have the cDNAs encoding chimeric
SUR I through VI, IX through XIV (20), and XVII (21) (see Fig. 1,
left panel). These chimeras were constructed initially to
allow swapping of seven major domains of SUR using existing restriction
sites in human SUR1 and SUR2A and, when missing, by engineering
matching restriction sites. The new chimeras, XIX through XXIV, were
constructed by swapping the indicated segments (Fig. 1). The
co-transfection with SUR and KIR6.2 and the cultivation of
COSm6 cells was done as described (15). Recording of currents from
inside-out patches was done at 22-24 °C as described previously
(15) using an Axopatch 200B amplifier (Axon Instruments, Inc., Foster
City, CA) at a holding potential of 40 mV. Pipettes were filled up
with the K+-rich external solution containing (in
mM) 145 KCl, 1 MgCl2, 1 CaCl2, 10 HEPES, pH 7.4 (KOH). The Mg2+-free internal solution was
(in mM) 140 KCl, 5 EDTA, 5 HEPES, 10 KOH, pH 7.2 (KOH),
whereas the Mg2+-containing "intracellular" solution
was (in mM) 140 KCl, 1 MgCl2, 5 EGTA, 5 HEPES,
10 KOH, pH 7.2 (KOH). Pinacidil was from Lilly Research Laboratories,
and ATP (ultra-pure, di-sodium salt) and other compounds were from
Sigma. The free Mg2+ concentration in all
Mg2+-containing internal solutions was maintained at a
quasi-cytosolic level of ~0.7 mM, as described previously
(15). Tolbutamide (200 mM stock solution in 0.1 N KOH) was
added to the nucleotide-free internal solution to a final concentration
of 200 µM. Diazoxide, cromakalim, or pinacidil (100 mM stock solutions in dimethyl sulfoxide, Me2SO) were added to the 0.1 mM ATP- and
Mg2+-containing internal solution. The final concentrations
were 300 µM diazoxide (0.3 volume % Me2SO),
200 µM cromakalim, or 100 µM pinacidil.
Bathing solutions were applied using a programmable rapid solution
changer (RSC-200, Biologic Inc, Claix, France). The relative NPo, used
as a measure of channel activity in the presence of a test compound,
was estimated as described previously (15) after applying corrections
for run-down and for reactivation by Mg-ATP. Addition of 0.3 volume % Me2SO to the ~0.1 mM Mg-ATP containing
internal solution induced a small, 1.25 ± 0.26- and 1.27 ± 0.28-fold, increase in the NPo values of -cell and cardiac KATP channels, respectively (mean ± S.D.).
The latter estimate was used to define the lower limit for a
significant increase in the averaged NPo values, expressed as mean ± S.D., in the presence of either KCO (see Fig. 1). The differences in
NPo values with p < 0.05 (unpaired Student's
t test) were considered significant.
 |
RESULTS |
In agreement with our original demonstration (8), the
SUR1/KIR6.2 and SUR2A/KIR6.2 channels display
differences in sulfonylurea sensitivity and in responsiveness to
diazoxide and cromakalim (Fig. 1). The
SUR1/KIR6.2 channel currents, activated upon excision of an
inside-out patch into nucleotide-free internal solution, are inhibited
by ~60% by 200 µM tolbutamide, a concentration which saturates the high-affinity binding site (21), whereas the
SUR2A/KIR6.2 channels are inhibited by ~15% (15) as a
result of low-affinity interaction(s) (21). With ~0.1 mM
Mg-ATP in the internal solution to ensure maximal binding of KCOs
(11-13) and pre-inhibit channel activity, a supra-pharmacological
concentration of diazoxide, 300 µM, sufficient to
half-maximally saturate SUR1 and SUR2 (13), significantly attenuated
nucleotide-inhibition of SUR1/KIR6.2, but not
SUR2A/KIR6.2, channels. A concentration of cromakalim, sufficient to saturate SUR2A, almost completely antagonized the inhibition of SUR2A/KIR6.2 channels by 0.1 mM
ATP but did not stimulate SUR1/KIR6.2 channels. In the
absence of either, or both, nucleotides and Mg2+
(~10 9 M free Mg2+ in the
Mg2+-free internal solution), stimulation by diazoxide was
undetectable and stimulation by cromakalim or pinacidil was reduced
~10-fold (not shown). The remaining nonphysiologic effect of
cromakalim in the absence of Mg-ATP was not examined further.

View larger version (43K):
[in this window]
[in a new window]
|
Fig. 1.
Delineation of SUR segments that specify
differences in the pharmacologic profiles of
SUR1/KIR6.2 versus
SUR2A/KIR6.2 channels. The left
panel illustrates the SUR chimeras used (see Refs. 20 and 21 for
descriptions) with the topology of SUR (29) at the top and
numbering of amino acids at the bottom. Segments from SUR1
and SUR2A are shown in white and gray,
respectively. The middle panel shows records of current
through SUR/KIR6.2 channels. The thin horizontal
line shows the level of currents when KATP
channels are closed; downward deflections correspond to inward
currents. A 15 s bar is shown near each trace. The
current bars are (in pA): 10, chimera XIX, and XXI through XXIII; 20, SUR2A, chimeras II through VI, IX through XI, and XX; 50, chimeras I,
XIV, XVII, and XXIV; 100, SUR1, and chimera XIII; and 500, chimera XII.
The different horizontal bars indicate applications of ATP
or drugs, as indicated. The record of macrocurrent through chimera
XII/KIR6.2 channels shows the slower wash-out for the
cromakalim versus diazoxide stimulation; the vertical
arrow above the trace indicates the application of 1 mM ATP. All of the chimeric channels were more inhibited by
0.1 mM ATP in the presence than absence of Mg2+
(20), and all were more inhibited than homomeric KIRs (14,
27, 28), implying that interactions mediating the SUR-induced increase
in apparent ATP-sensitivity of KIR and Mg-ATP stimulation
were preserved in all of the chimeras. The right panel gives
a comparison of tolbutamide inhibition and stimulation by KCOs. For
each patch, the NPo value in the presence of tolbutamide was normalized
to that in nucleotide-free internal solution, and the NPo value in the
presence of the KCO was normalized to that at 0.1 mM ATP
with Mg2+. The relative NPo values 1 are plotted on an
expanded scale. The two thin vertical lines indicate the
interval where NPo changes were insignificant (see "Experimental
Procedures"). All data points with a mean value (± S.D.) outside
this interval represent significant effects (p < 0.05)
with the exception of diazoxide stimulation of chimeras
XI/KIR6.2 and XXII/KIR6.2 channels where
p < 0.1.
|
|
Comparison of the stimulation of chimeric SUR/KIR6.2
channels by diazoxide and cromakalim demonstrated all four possible
types of channels including those differentially responsive to the two compounds, those that failed to respond to either drug and those that
responded to both drugs. Analysis of six pairs of matched chimeric SURs
(Fig. 1, underlined) suggested that stimulation by
cromakalim was determined by the presence of TMD12-17 from SUR2 in the
chimeric receptor (chimeras V through XII), whereas matched channels
lacking this segment were not stimulated by cromakalim. Stimulation by
diazoxide was correlated with the presence of either NBF1 and TMD6-11
from SUR1 (chimeras I through III and XII through XIV, and XI,
respectively). Chimeras II and XII, containing both NBF1 and TMD6-11
of SUR1 conferred the maximal response to diazoxide, whereas chimera
XI, containing TMD6-11 of SUR1 and NBF1 of SUR2, specified a lower
efficacy response. Analysis of three additional pairs of chimeras with
reciprocally exchanged single segments reinforces the conclusion that
TMD12-17 of SUR2 confers a selective interaction with either
cromakalim or pinacidil, whereas TMD6-11 and NBF1 of SUR1 contribute
additively to diazoxide responsiveness. Substitution of TMD6-11 and
NBF1 of SUR1 into SUR2A (chimera XXIV) was essential for maximal
response to diazoxide.
The separable nature of the segments that specify the selective
responses of KATP channel isoforms to the two
KCOs is demonstrated by the generation of channels that are stimulated
by both the " -cell specific" and "cardiovascular" KCOs
(chimeras XII, XIX through XXI, and XXIV) versus those that
are not stimulated by either KCO (chimera IV and chimera XVII). The
inhibition (~60%) of these KCO-insensitive currents by 200 µM tolbutamide ensured that TMD12-17 was functionally
coupled to KIR6.2 (21). A direct comparison of currents
through the channels responding to both types KCOs suggests a slower
off-rate for the benzothiadiazine or pyridine versus
benzopyran KCOs.
 |
DISCUSSION |
The results show that two separate regions in SURs are necessary
to determine the selective effects of diazoxide versus
cromakalim or pinacidil. We propose that segment(s) of SUR2, from the
glutamate-rich motif following NBF1 through the intracellular segment
preceding NBF2 (red tones in Fig.
2), confer sensitivity to the benzopyran and pyridine derivatives, whereas TMD6-11 and NBF1 of SUR1 specify a
-cell channel-like response to the pyrimidine KCO, diazoxide. Our
demonstration that TMD12-17 of SUR2 is required for cromakalim stimulation of human KATP channels complements
the observation of D'Hahan et al. (18) that transfer of
TMD12-17 from rat SUR2A into hamster SUR1 is sufficient for
SR47063-responsiveness of chimeric SUR/KIR6.2 channels and
complements the report by Uhde et al. (19) that smaller
segments, Thr1059-Leu1087 and
Arg1218-Asn1320, of rat SUR2 confer specific
binding of [3H]P1075, displaceable by pinacidil and
levcromakalim, when placed in a hamster SUR1 background. These results
imply, but do not prove, that TMD12-17 is essential to form a KCO
binding pocket. D'Hahan et al. (18) used a limited number
of chimeras and were unable to delineate a region critical for the
selective action of diazoxide, while Uhde et al. (19)
assumed TMD12-17 was sufficient to determine the response to different
KCOs and did not examine the effects of diazoxide. Using a matched set
of SUR chimeras, we show the action of diazoxide requires more than
TMD12-17. The demonstration that stimulation by diazoxide involves
domains of SUR1 other than TMD12-17 suggests these domains either
couple diazoxide binding at TMD12-17, or at another segment, to the
KIR6.2 gating mechanism or form an additional KCO-binding
site. Consistent with a coupling mechanism, diazoxide can displace
[3H]P1075 from SUR2B, and [3H]glibenclamide
from SUR1, yielding similar apparent KD values for both SUR1 and SUR2 isoforms (13) and can stimulate both KATP channel isoforms (16, 17). The results are
compatible with a minimal model in which different classes of KCOs,
including diazoxide, occupy the same site in TMD12-17 and that this
site, in SUR1, is in close proximity to sulfonylurea binding pocket (19, 21, 23). The proximity of these sites implies the potential for
negative allosteric interactions. We infer that multiple regions of SUR
contribute to coupling KCO-occupied site(s) with the KIR gating machinery. In SUR1/KIR6.2 channels, efficient
coupling of diazoxide binding requires TMD6-11 and NBF1, whereas the C terminus is important in SUR2B/KIR6.2 channels. The
involvement of NBF1 in stimulation by diazoxide suggests nucleotide
binding and/or hydrolysis could contribute to the efficacy of this
compound. This would be consistent with diazoxide stimulation of
SUR2A/KIR6.2 channels under conditions which may saturate
ADP binding (16) and with isoform differences in the sequences of NBF1.
NBF1 and NBF2 are known to serve different functions (24), and we have observed more efficient stimulation of -cell versus
cardiac KATP channels by increasing the
[ADP]/[ATP] ratio.2 Based
on four lines of evidence that 1) the analogous TMD12-17 segment of
MRP, a structurally related transport ATPase, is important for
conferring drug-resistance (25), 2) substrates are known to activate
the ATPase activity of transport ATPases, 3) hydrolyzable Mg-ATP is
required for KCO action, and 4) KATP channel
stimulation is regulated by changes in the [ATP]/[ADP] ratio, we
hypothesize that KCOs increase an ATPase activity of SUR and/or
stabilize Mg-ADP on NBF2 of SUR (24). Within this framework, the
requirement of Mg-ATP for KCO binding could reflect an ordered ATP
hydrolytic mechanism and suggests KCOs may be transported. This
suggests that drug binding to TMD12-17 and cooperative binding (24) of ATP and Mg-ADP to NBF1 and NBF2, respectively, may influence each other
allosterically. This would explain the requirement for Mg-ATP and
intact NBFs for KCO binding (13), modulation of this binding by Mg-ADP
(26), and sulfonylurea-inhibition of the stimulatory action of
nucleotides (21), and the release of pre-bound 8-N3ATP from
SUR1 by sulfonylureas (24) (as illustrated in Fig. 2).

View larger version (58K):
[in this window]
[in a new window]
|
Fig. 2.
A summary schematic showing the
determinants and interactions which specify differential modulation of
(SURx/KIR6.0)4 channels
by nucleotides, KCOs, and sulfonylureas. Two
SURx/KIR6.0 pairs are shown with SUR1 and SUR2A surrounding
a central KIR6.2 pore. The -helix, beginning at
Arg50, and -strands in the KIR N terminus
are based on secondary structure predictions (30). Truncation of >44
N-terminal amino acids from KIR6.2 inhibits functional
expression of KATP channels, indicating possible
involvement of this region in co-assembly, while substitution of a Gln
at Arg50 affects gating of
SUR1/KIR6.2K185Q channels, implying there are
interactions between the cytoplasmic sequences adjacent to M1 and M2
(31). We speculate that nucleotide-sensitive conformational changes in
the cytoplasmic domains of KIR modulate
nucleotide-independent motions of M2 helices that control gated access
to the pore. The swapped segments of SURs are colored differently.
TMD1-5 is placed near the N terminus of KIR6.2 because the
N-terminal segments of SUR, including the long intracellular loop
between TMD5 and 6 (32) and the N terminus of KIR6.2, are
involved in controlling spontaneous bursting of
KATP channels (20, 31). The C terminus of SUR is
near the segment of KIR6.2 from Glu179 through
Leu355 which has been assumed to contain a low-affinity
nucleotide-binding site (14, 27, 28) and "linker domain" (33) since
the last 42 amino acids of SUR1 specify, independently of the
Po(max), a lower steady-state
IC50(ATP) in -cell versus sarcolemmal
KATP channels (20). The separable effects of SUR
on the occupancy of the K+ driving force-independent closed
state and on the IC50(ATP) suggest that ATP may bind to
KIR6.2 in both closed and open conformations. Tolbutamide
(Tlb), whose sulfonylurea moiety is identical to that in
glibenclamide, is positioned near cytoplasmic loops of TMD12-17 of
SUR1 based on identification of the segment(s) required for
high-affinity tolbutamide inhibition and
[3H]glibenclamide binding (19, 21, 23). The SUR segments
which specify stimulation by diazoxide versus cromakalim or
pinacidil are color-coded (blue versus red
tones). The two darker segments in TMD12-17 of SUR2
are the predicted cytoplasmic regions which may form a KCO binding
pocket based on [3H]P1075 binding (19) and thus match the
color of pinacidil (Pin). Cromakalim (Crm), a
less potent KCO, is shown displaced from the pocket. The equivalent
segments in SUR1 are unavailable when the intervening sulfonylurea
pocket is occupied (19); this provides a mechanistic explanation for
the apparent negative allosterism between sulfonylurea- and diazoxide-
(Dzx) binding. The "trees" identify the glycosylation
sites (note differences between SUR isoforms). The glutamate-rich motif
is indicated by EEE. The ER retention (34) and putative
anterograde (35) signals, controlling surface expression of
(SURx/KIR6.0)4 channels, are indicated by
rrr and aaa, respectively. Interestingly, the rrr
of SUR2 contains RKQ versus RKR in SUR1, and the numbers of
channels with the regulatory subunits containing the rrr region of SUR1
appear to be higher in comparable patches (note different current
scales for representative records in Fig. 1).
|
|
Fig. 2 presents a summary model integrating currently available data on
the functional topology of SURs. In addition to sequences in TMD1-5
and the C terminus that specify differences in
Po(max) and IC50(ATP) of
KATP channel isoforms (20), results from four groups (18, 19, 21, 23) demonstrate that TMD12-17 is critical for the
action of both sulfonylureas and KCOs, suggesting this region forms the
binding pockets for these compounds. Subdivision of TMD12-17 of SUR1
implicates intracellular loops in high-affinity sulfonylurea binding
(19, 21, 23). The corresponding regions in SUR2 separates sequences
required for high-affinity binding of [3H]P1075.
Contribution of separate domains to coupling the energy of binding to
re-configurations of the channel gate show the molecular mechanism of
action of these drugs cannot be understood simply in terms of drug
binding sites. Recent studies (13, 14) have largely eliminated early
models based on direct competition for a nucleotide binding site. The
relative currents in the presence of ~0.1 mM Mg-ATP and
200 µM cromakalim (see also Ref. 18) are higher than
expected if KCOs "uncouple" SUR from KIR6.2 and thus eliminate the ability of SUR to increase the sensitivity of
KIR6.0 to ATP, judged by comparing the
IC50(ATP) of heteromeric versus homomeric
channels (14, 27, 28). The data argue that KCOs have a net
stimulatory effect, beyond the ~9-fold and ~33-fold decrease in
IC50(ATP) induced by SUR2A and SUR1, respectively (20, 27).
We propose that there is no requirement for a decrease in the affinity
of the putative ATP-inhibitory site on KIR6.0 or need for
dissociation of ATP for KCOs to open KATP
channels. Our finding that the first half of the N terminus of
KIR6.2 "couples" high-affinity sulfonylurea- but not
diazoxide-binding to SUR1 with KIR gate (21) implies there
are at least two parallel pathways through which SURs can
converse with the KIR6.0 pore gate.
 |
ACKNOWLEDGEMENTS |
We thank Li-Zhen Song for excellent technical
assistance with cell culture and transfections.
 |
FOOTNOTES |
*
The work was supported by grants from Juvenile Diabetes
Foundation International and American Heart Association (to A. P. B.)
and by National Institutes of Health grants (to J. B.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: Tel.: 713-798-4996;
Fax: 713-790-0545; E-mail: ababenko@bcm.tmc.edu.
2
A. P. Babenko, unpublished data.
 |
ABBREVIATIONS |
The abbreviations used are:
KCO, K+
channel opener;
SUR, sulfonylurea receptor;
KATP, (SURx/KIR6.0)4
channels;
NBF, nucleotide binding fold;
IC50(ATP), IC50 value for ATP;
Po(max), the
maximal mean open channel probability in the absence of nucleotides;
TMD, transmembrane domain.
 |
REFERENCES |
| 1.
|
Edwards, G.,
and Weston, A. H.
(1993)
Annu. Rev. Pharmacol. Toxicol.
33,
597-637[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Noma, A.
(1983)
Nature
305,
147-148[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Cook, D. L.,
and Hales, C. N.
(1984)
Nature
311,
271-273[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Trube, G.,
Rorsman, P.,
and Ohno-Shosaku, T.
(1986)
Pfluegers Arch. Eur. J. Physiol.
407,
493-499[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Escande, D.,
Thuringer, D.,
Leguern, S.,
and Cavero, I.
(1988)
Biochem Biophys. Res. Commun.
154,
620-625[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Aguilar-Bryan, L.,
Nichols, C. G.,
Wechsler, S. W.,
Clement, J. P., IV,
Boyd, A. E., III,
Gonzalez, G.,
Herrera-Sosa, H.,
Nguy, K.,
Bryan, J.,
and Nelson, D. A.
(1995)
Science
268,
423-426[Abstract/Free Full Text]
|
| 7.
|
Inagaki, N.,
Gonoi, T.,
Clement, J. P., IV,
Namba, N.,
Inazawa, J.,
Gonzalez, G.,
Aguilar-Bryan, L.,
Seino, S.,
and Bryan, J.
(1995)
Science
270,
1166-1170[Abstract/Free Full Text]
|
| 8.
|
Inagaki, N.,
Gonoi, T.,
Clement, J. P., IV,
Wang, C. Z.,
Aguilar-Bryan, L.,
Bryan, J.,
and Seino, S.
(1996)
Neuron
16,
1011-1017[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Babenko, A. P.,
Aguilar-Bryan, L.,
and Bryan, J.
(1998)
Annu. Rev. Physiol.
60,
667-687[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Arena, J. P.,
and Kass, R. S.
(1989)
Am. J. Physiol.
257,
H2092-H2096[Abstract/Free Full Text]
|
| 11.
|
Dickinson, K. E.,
Bryson, C. C.,
Cohen, R. B.,
Rogers, L.,
Green, D. W.,
and Atwal, K. S.
(1997)
Mol. Pharmacol.
52,
473-481[Abstract/Free Full Text]
|
| 12.
|
Hambrock, A.,
Loffler-Walz, C.,
Kurachi, Y.,
and Quast, U.
(1998)
Br. J. Pharmacol.
125,
577-583[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Schwanstecher, M.,
Sieverding, C.,
Dorschner, H.,
Gross, I.,
Aguilar-Bryan, L.,
Schwanstecher, C.,
and Bryan, J.
(1998)
EMBO J
17,
5529-5535[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Tucker, S. J.,
Gribble, F. M.,
Zhao, C.,
Trapp, S.,
and Ashcroft, F. M.
(1997)
Nature
387,
179-183[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Babenko, A. P.,
Gonzalez, G.,
Aguilar-Bryan, L.,
and Bryan, J.
(1998)
Circ. Res.
83,
1132-1143[Abstract/Free Full Text]
|
| 16.
|
D'Hahan, N.,
Moreau, C.,
Prost, A. L.,
Jacquet, H.,
Alekseev, A. E.,
Terzic, A.,
and Vivaudou, M.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
12162-12167[Abstract/Free Full Text]
|
| 17.
|
Isomoto, S.,
Kondo, C.,
Yamada, M.,
Matsumoto, S.,
Higashiguchi, O.,
Horio, Y.,
Matsuzawa, Y.,
and Kurachi, Y.
(1996)
J. Biol. Chem.
271,
24321-24324[Abstract/Free Full Text]
|
| 18.
|
D'Hahan, N.,
Jacquet, H.,
Moreau, C.,
Catty, P.,
and Vivaudou, M.
(1999)
Mol. Pharmacol.
56,
308-315[Abstract/Free Full Text]
|
| 19.
|
Uhde, I.,
Toman, A.,
Gross, I.,
Schwanstecher, C.,
and Schwanstecher, M.
(1999)
J. Biol. Chem.
274,
28079-28082[Abstract/Free Full Text]
|
| 20.
|
Babenko, A. P.,
Gonzalez, G.,
and Bryan, J.
(1999)
J. Biol. Chem.
274,
11587-11592[Abstract/Free Full Text]
|
| 21.
|
Babenko, A. P.,
Gonzalez, G.,
and Bryan, J.
(1999)
FEBS Lett.
459,
367-376[CrossRef][Medline]
[Order article via Infotrieve]
|
| 22.
|
Aguilar-Bryan, L.,
Clement, J. P., IV,
Gonzalez, G.,
Kunjilwar, K.,
Babenko, A.,
and Bryan, J.
(1998)
Physiol. Rev.
78,
227-245[Abstract/Free Full Text]
|
| 23.
|
Ashfield, R.,
Gribble, F. M.,
Ashcroft, S. J.,
and Ashcroft, F. M.
(1999)
Diabetes
48,
1341-1347[Abstract]
|
| 24.
|
Ueda, K.,
Komine, J.,
Matsuo, M.,
Seino, S.,
and Amachi, T.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
1268-1272[Abstract/Free Full Text]
|
| 25.
|
Stride, B. D.,
Cole, S. P.,
and Deeley, R. G.
(1999)
J. Biol. Chem.
274,
22877-22883[Abstract/Free Full Text]
|
| 26.
|
Hambrock, A.,
Loffler-Walz, C.,
Kloor, D.,
Delabar, U.,
Horio, Y.,
Kurachi, Y.,
and Quast, U.
(1999)
Mol. Pharmacol.
55,
832-840[Abstract/Free Full Text]
|
| 27.
|
Babenko, A. P.,
Gonzalez, G.,
Aguilar-Bryan, L.,
and Bryan, J.
(1999)
FEBS Lett.
445,
131-136[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Drain, P.,
Li, L.,
and Wang, J.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
13953-13958[Abstract/Free Full Text]
|
| 29.
|
Tusnady, G. E.,
Bakos, E.,
Varadi, A.,
and Sarkadi, B.
(1997)
FEBS Lett.
402,
1-3[CrossRef][Medline]
[Order article via Infotrieve]
|
| 30.
|
Rost, B.,
Sander, C.,
and Schneider, R.
(1994)
Comput. Appl. Biosci.
10,
53-60[Abstract/Free Full Text]
|
| 31.
|
Babenko, A. P.,
Gonzalez, G.,
and Bryan, J.
(1999)
Biochem. Biophys. Res. Commun.
255,
231-238[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
Raab-Graham, K. F.,
Cirilo, L. J.,
Boettcher, A. A.,
Radeke, C. M.,
and Vandenberg, C. A.
(1999)
J. Biol. Chem.
274,
29122-29129[Abstract/Free Full Text]
|
| 33.
|
Babenko, A. P., Sharma, N., Aguilar-Bryan, L., Gonzalez, G., and Bryan, J.
(eds)
(1999)
in
Frontiers in Diabetes
(Matschinsky, F. M.
, and Magnuson, M. A., eds)
, pp. 300-317, Karger, Basel, Switzerland
|
| 34.
|
Zerangue, N.,
Schwappach, B.,
Jan, Y. N.,
and Jan, L. Y.
(1999)
Neuron
22,
537-548[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Sharma, N.,
Crane, A.,
Clement, J. P., IV,
Gonzalez, G.,
Babenko, A. P.,
Bryan, J.,
and Aguilar-Bryan, L.
(1999)
J. Biol. Chem.
274,
20628-20632[Abstract/Free Full Text]
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
T. P. Flagg, H. T. Kurata, R. Masia, G. Caputa, M. A. Magnuson, D. J. Lefer, W. A. Coetzee, and C. G. Nichols
Differential Structure of Atrial and Ventricular KATP: Atrial KATP Channels Require SUR1
Circ. Res.,
December 5, 2008;
103(12):
1458 - 1465.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Hiriart and L. Aguilar-Bryan
Channel regulation of glucose sensing in the pancreatic {beta}-cell
Am J Physiol Endocrinol Metab,
December 1, 2008;
295(6):
E1298 - E1306.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Farzaneh and A. Tinker
Differences in the mechanism of metabolic regulation of ATP-sensitive K+ channels containing Kir6.1 and Kir6.2 subunits
Cardiovasc Res,
September 1, 2008;
79(4):
621 - 631.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Ng, Y. Kang, C. L. Elias, Y. He, H. Xie, J. B. Hansen, P. Wahl, and H. Y. Gaisano
The Actions of a Novel Potent Islet {beta}-Cell Specific ATP-Sensitive K+ Channel Opener Can Be Modulated by Syntaxin-1A Acting on Sulfonylurea Receptor 1
Diabetes,
August 1, 2007;
56(8):
2124 - 2134.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Li, X. Geng, M. Yonkunas, A. Su, E. Densmore, P. Tang, and P. Drain
Ligand-dependent Linkage of the ATP Site to Inhibition Gate Closure in the KATP Channel
J. Gen. Physiol.,
August 29, 2005;
126(3):
285 - 299.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Bryan, W. H. Vila-Carriles, G. Zhao, A. P. Babenko, and L. Aguilar-Bryan
Toward Linking Structure With Function in ATP-Sensitive K+ Channels
Diabetes,
December 1, 2004;
53(suppl_3):
S104 - S112.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Hambrock, T. Kayar, D. Stumpp, and H. Osswald
Effect of Two Amino Acids in TM17 of Sulfonylurea Receptor SUR1 on the Binding of ATP-Sensitive K+ Channel Modulators
Diabetes,
December 1, 2004;
53(suppl_3):
S128 - S134.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. V. Avshalumov and M. E. Rice
Activation of ATP-sensitive K+ (KATP) channels by H2O2 underlies glutamate-dependent inhibition of striatal dopamine release
PNAS,
September 30, 2003;
100(20):
11729 - 11734.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Chen, Y. Dong, and J. M. Simard
Functional Coupling between Sulfonylurea Receptor Type 1 and a Nonselective Cation Channel in Reactive Astrocytes from Adult Rat Brain
J. Neurosci.,
September 17, 2003;
23(24):
8568 - 8577.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. I. Rosenblum
ATP-Sensitive Potassium Channels in the Cerebral Circulation
Stroke,
June 1, 2003;
34(6):
1547 - 1552.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. A. Cartier, S. Shen, and S.-L. Shyng
Modulation of the Trafficking Efficiency and Functional Properties of ATP-sensitive Potassium Channels through a Single Amino Acid in the Sulfonylurea Receptor
J. Biol. Chem.,
February 21, 2003;
278(9):
7081 - 7090.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Reimann, M. Dabrowski, P. Jones, F. M Gribble, and F. M Ashcroft
Analysis of the differential modulation of sulphonylurea block of {beta}-cell and cardiac ATP-sensitive K+ (KATP) channels by Mg-nucleotides
J. Physiol.,
February 15, 2003;
547(1):
159 - 168.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. P. Babenko and J. Bryan
SUR-dependent Modulation of KATP Channels by an N-terminal KIR6.2 Peptide. DEFINING INTERSUBUNIT GATING INTERACTIONS
J. Biol. Chem.,
November 8, 2002;
277(46):
43997 - 44004.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Hambrock, R. Preisig-Muller, U. Russ, A. Piehl, P. J. Hanley, J. Ray, J. Daut, U. Quast, and C. Derst
Four novel splice variants of sulfonylurea receptor 1
Am J Physiol Cell Physiol,
August 1, 2002;
283(2):
C587 - C598.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Dabrowski, F. M. Ashcroft, R. Ashfield, P. Lebrun, B. Pirotte, J. Egebjerg, J. Bondo Hansen, and P. Wahl
The Novel Diazoxide Analog 3-Isopropylamino-7-Methoxy-4H-1,2,4-Benzothiadiazine 1,1-Dioxide Is a Selective Kir6.2/SUR1 Channel Opener
Diabetes,
June 1, 2002;
51(6):
1896 - 1906.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. V. Zingman, D. M. Hodgson, M. Bienengraeber, A. B. Karger, E. C. Kathmann, A. E. Alekseev, and A. Terzic
Tandem Function of Nucleotide Binding Domains Confers Competence to Sulfonylurea Receptor in Gating ATP-sensitive K+ Channels
J. Biol. Chem.,
April 12, 2002;
277(16):
14206 - 14210.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Loffler-Walz, A. Hambrock, and U. Quast
Interaction of KATP Channel Modulators with Sulfonylurea Receptor SUR2B: Implication for Tetramer Formation and Allosteric Coupling of Subunits
Mol. Pharmacol.,
February 1, 2002;
61(2):
407 - 414.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Hambrock, C. Loffler-Walz, U. Russ, U. Lange, and U. Quast
Characterization of a Mutant Sulfonylurea Receptor SUR2B with High Affinity for Sulfonylureas and Openers: Differences in the Coupling to Kir6.x Subtypes
Mol. Pharmacol.,
July 1, 2001;
60(1):
190 - 199.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
F. Reimann, F. M. Gribble, and F. M. Ashcroft
Differential Response of KATP Channels Containing SUR2A or SUR2B Subunits to Nucleotides and Pinacidil
Mol. Pharmacol.,
April 13, 2001;
58(6):
1318 - 1325.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
B. O'Rourke
Myocardial KATP Channels in Preconditioning
Circ. Res.,
November 10, 2000;
87(10):
845 - 855.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Matsuoka, K. Matsushita, Y. Katayama, A. Fujita, K. Inageda, M. Tanemoto, A. Inanobe, S. Yamashita, Y. Matsuzawa, and Y. Kurachi
C-Terminal Tails of Sulfonylurea Receptors Control ADP-Induced Activation and Diazoxide Modulation of ATP-Sensitive K+ Channels
Circ. Res.,
November 10, 2000;
87(10):
873 - 880.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. P. Babenko, G. C. Gonzalez, and J. Bryan
Hetero-concatemeric KIR6.X4/SUR14 Channels Display Distinct Conductivities but Uniform ATP Inhibition
J. Biol. Chem.,
October 6, 2000;
275(41):
31563 - 31566.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Matsuo, K. Tanabe, N. Kioka, T. Amachi, and K. Ueda
Different Binding Properties and Affinities for ATP and ADP among Sulfonylurea Receptor Subtypes, SUR1, SUR2A, and SUR2B
J. Biol. Chem.,
September 8, 2000;
275(37):
28757 - 28763.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. R. Conti, C. M. Radeke, S.-L. Shyng, and C. A. Vandenberg
Transmembrane Topology of the Sulfonylurea Receptor SUR1
J. Biol. Chem.,
October 26, 2001;
276(44):
41270 - 41278.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. P. Babenko and J. Bryan
A Conserved Inhibitory and Differential Stimulatory Action of Nucleotides on KIR6.0/SUR Complexes Is Essential for Excitation-Metabolism Coupling by KATP Channels
J. Biol. Chem.,
December 21, 2001;
276(52):
49083 - 49092.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2000 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|